More Business Wire
View Older Stories View Newer Stories-
Cambridge GaN Devices’ Unique 2D Barcodes Increase Process Ruggedness and Reliability
-
Peregrine Hydrogen Announces Financing to Accelerate the Development of its Co-Production Technology for Clean Hydrogen and Valuable Commodity Chemicals
-
USMI to Debut the Canady Robotic AI Surgical System at the First Global Surgical Oncology Summit Jerusalem, Israel January 2024
-
Dame Olivia Newton-John’s Totally Hot Celebrates 45th Anniversary With a Sizzling Return to Vinyl and CD on November 17
-
AMTD IDEA Group Increases Share Repurchase Program by US$20 million
-
AMTD Digital Inc. Increases Share Repurchase Program by US$20 million
-
AM Best Revises Issuer Credit Rating Outlook to Negative for Shelter Mutual Insurance Company and Its Subsidiaries
-
Chris Rock brings Las Vegas to the UK in BetMGM’s launch advertising campaign
-
Global Press Conference on Discovering Changjiang Civilization Through Culture, Ecology and Transportation Was Successfully Held in Hefei, East China’s Anhui Province
-
Intuit Launches Food Truck Program to Empower Underserved Youth with Vital Financial, Technical and Entrepreneurial Skills
-
Barnes Aerospace Announces Two Extended Long-Term Agreements with Safran
-
Coya Therapeutics Licenses Exclusive Worldwide rights to Exosome Engineering Technology (EET) from Carnegie Mellon University (CMU)
-
indie Semiconductor Commences Warrant Exchange Offer and Consent Solicitation
-
NYSE to Commence Delisting Proceedings with Respect to the Warrants of Fathom Digital Manufacturing Corporation (FATH.WS)
-
Treasury Partners Founder Richard Saperstein Named to the Barron’s Top 100 Independent Advisors List
-
Southern Glazer’s Wine & Spirits Announces Retirement of John Klein, Executive Vice President and General Manager, Pacific Northwest
-
Qihan Biotech announces the completion of pre-Series B financing for developing stem cell-derived cell therapy products with high-throughput multiplexable genome editing
-
Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and
-
Idomoo Announces Commercial Launch of Lucas, AI Video Creator
-
Settlement Administrator Angeion Group Announces Proposed Settlement In U.S. Dollar LIBOR-Based Instrument Class Action
-
Phil Breden and Wemotaci, Que. Awarded Prestigious Roger Cyr Awards for Rail Safety
-
Allego N.V. Announces Extension of Exchange Offer and Consent Solicitation Relating to Warrants
-
First Foundation Advisors Recognized as a Top Registered Investment Advisory Firm by Barron’s
-
OFG Bancorp to Report 3Q23 Results and Hold Call Friday, October 20, 2023
-
KLDiscovery Inc. Announces Agreement to Acquire Cenza Technologies Private Limited to Establish Global Delivery Center in India
-
Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement
-
MariaDB Receives NYSE Continued Listing Standards Notice
-
Metro Vancouver Rogers Workers Vote 99.6% in Favour of Strike Action
-
ExoDexa Acquires Perpetual License to Evolved Play IP
-
Redfin Reports Pending Home Sales Drop 13% Year Over Year As Mortgage Rates Stay Stubbornly High
-
Missouri American Water Announces Recipients of 2023 Firefighter Grant Program
-
Nanaz Mohtashami Elected to Hologic Board of Directors
-
East West Bancorp Announces Date for Third Quarter 2023 Financial Results
-
Laser Photonics’ MarkStar Streamlines Inventory Management in the Automotive Industry
-
Thomas R. Nides to Join Wells Fargo as Vice Chairman
-
ECM Wins 2023 IDEA Awards for its PrintStator Electric Motor CAD Software
-
Pebblebrook Hotel Trust Provides Operating Update
-
Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Br
-
Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectab
-
Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer
-
Kenvue to Announce Third Quarter 2023 Results on October 26, 2023
-
Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced
-
Vizient Announces Top Performers in Clinical Quality, Supplier Diversity and Environmentally Preferred Sourcing Excellence
-
OS Achieves 800-Puff Milestone with FEELM Max Technology
-
truvami Launches Tiny B2B Tracking Solution for In- and Outdoor Visibility of Assets.
-
Calix To Continue 24-Year Leadership in US Rural Broadband, Affirming Commitment to BEAD ‘Build America, Buy America’
-
PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in
-
Mitsubishi Electric Announces Dividend Policy for the First Half of Fiscal 2024
-
CLF Innovative Mold Height Setting and Clamping System: A Breakthrough in Two Platen Injection Molding Machine
-
Europe’s Enterprises Look to Providers to Bridge the CX Gap
